Fig. A1a)-r) Box plots for the investigated parameters dependent on the IP strategy i)/ ii)/ iii).

Abbreviations: i) "maximize coverage favor selectivity"; ii) "maximize coverage favor BOT"; iii) "maximize selectivity".
Fig. A2a-r) Comparison between benign and malignant entities for the investigated parameters.

The upper box plots of the respective subfigures (a)-r) represent the results for benign entities (meningiomas, neurinomas, adenomas and ACNs) and the lower boxplots for malignant disorders (singular and multiple cerebral (micro-)metastases). The left and middle box plots for each subfigure display the outcomes according to the different strategies (same notation as in Figure A1), and the right box plots for each subfigure regardless of the strategy. As no OARs were considered in the treatment planning for malignant entities, the parameter $D_{\text{OAR transgression}}$ is not indicated. Abbreviations: i) "maximize coverage favor selectivity"; ii) "maximize coverage favor BOT"; iii) "maximize selectivity".
Fig. A3a-e) Results for micrometastases.

Abbreviations: i) "maximize coverage favor selectivity"; ii) "maximize coverage favor BOT"